There are no band aid treatments for GBM. Only surgery. There is no SOC that works.
Targeting a solid tumour cancer with CarT is ground breaking. Noone has gotten that to work yet. Remember they have preclinical data that suggests our CarT may be effective against several cancer types!
Noone had been able to fix the blood brain barrier problem when trying to treat GBM. So thats ground breaking. They have shown some disease control with lower doses. Lets see what the higher doses achieve, hopefully before the end of year.
So I dont think your wife has read this one correctly. If CHM gets its accelerated approval for. GBM, there will be no competitor drug. And, like keytruda, it could quickly roll into other indications after that.
Try to think of a valuation that would achieve.
The share price now, like most ASX biotechs, is not representative of future potential.
Next read out, and expansion trial could be company making pivots. But the market wont be interested until this is deriskesd significantly. And to this is a change from the 2019/2020 market sentiment.
CHM Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)